Eyepoint, Inc. insider trading
Every open-market purchase and sale by Eyepoint, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Eyepoint, Inc.’s insiders pay?
From October 3, 2012 to August 18, 2026, 19 insiders reported 23 open-market purchases and 12 sales not made under a pre-set plan in Eyepoint, Inc. Twelve months after each purchase was reported, the shares were −23.7% against the S&P 500 on average (median −27.8%), over 12 purchases with a full year of prices; 50% beat the index. After sales, the shares moved −70.0% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 16, 2022 into $32 by November 2, 2026, −71.3% a year. It held shares 84% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $16,455 (+11.4% a year), and held throughout $18,502 (+14.3%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | Other | 3 | −84.5% (3) | 0% | 1 | — | December 8, 2025 |
| Lurker Nancy | President & CEO | 4 | +12.0% (1) | 100% | 0 | — | August 20, 2024 |
| Zaderej Karen L. | Director | 4 | +54.5% (3) | 100% | 0 | — | August 18, 2026 |
| Essex Woodlands Ix, LLC | 10% owner | 1 | — | — | 2 | −40.8% (2) | September 1, 2023 |
| Cormorant Global Healthcare Master Fund, LP | 10% owner | 2 | −83.0% (2) | 0% | 0 | — | April 22, 2024 |
| Ew Healthcare Partners, L.P. | 10% owner | 0 | — | — | 2 | −42.4% (2) | September 6, 2023 |
| Ew Healthcare Partners-A, L.P. | 10% owner | 1 | — | — | 1 | −49.0% (1) | August 24, 2023 |
| Liu Ye | Director | 0 | — | — | 2 | −91.3% (2) | January 16, 2024 |
| Ocumension Therapeutics | Director | 0 | — | — | 2 | −91.3% (2) | January 16, 2024 |
| Ando Goran | Director | 1 | +16.3% (1) | 100% | 0 | — | August 21, 2024 |
| Dicicco Wendy F | Director | 1 | +16.3% (1) | 100% | 0 | — | August 21, 2024 |
| Duker Jay S. | President and CEO | 1 | — | — | 0 | — | March 16, 2026 |
| Elston George | Chief Financial Officer | 1 | — | — | 0 | — | November 18, 2019 |
| Godshall Douglas Evan | Director | 1 | — | — | 0 | — | April 1, 2019 |
| Hopper Paul | Director | 1 | — | — | 0 | — | October 3, 2012 |
| Jones David Scott | SVP & Chief Commercial Officer | 0 | — | — | 1 | −94.0% (1) | January 24, 2024 |
| Landis John B. | Director | 1 | — | — | 0 | — | May 15, 2019 |
| Paggiarino Dario A. | Chief Medical Officer | 0 | — | — | 1 | −95.8% (1) | January 25, 2024 |
| Pine Michael Craig | Chief Corp Dev.&Strat. Officer | 1 | −73.4% (1) | 0% | 0 | — | March 15, 2022 |
When several insiders traded Eyepoint, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Eyepoint, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −31.4% against the index. After 2 selling crowds, +33.8%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 30, 2024 | 4 buying | −8.3% | −30.6% | +16.1% |
| May 31, 2024 | 2 buying | −23.7% | −32.3% | −37.9% |
| January 31, 2024 | 4 selling | −37.0% | −79.3% | −98.8% |
| August 31, 2023 | 3 selling | −38.6% | +146.8% | −42.1% |